Document is current
Any future updates will be listed below
-
Authors
Szklarzewicz, Justyna
Floege, Ute
Gallego, Daniel
Gibson, Keisha
Kalantar-Zadeh, Kamyar
Helm, Kelly
Robinson, Dale
Schneider, Bonnie
Smith, Philip
Tullus, Kjell
Poyan-Mehr, Ali
Hendry, Bruce
Balkaran, Bridget L.
Jauregui, Adam K.
Wang, Aolin
Nason, Ian
Hazra, Nisha C.
Xu, Chunyi
Liu, Jingyi
Zhou, Zheng-Yi
Bensink, Mark https://orcid.org/0000-0002-5940-7898
-
Funding
Funding for this research was provided by:
Travere Therapeutics Inc.
- License Information
-
More Information
Article History
Accepted: 13 March 2025
First Online: 11 April 2025
Declarations
:
: Bruce Hendry is an employee of Travere Therapeutics, Inc. and holds stock/options. Mark Bensink is Managing Director of Benofit Consulting, which received consulting fees from Travere Therapeutics, Inc. for this work. Justyna Szklarzewicz, Ute Floege, Daniel Gallego, Keisha Gibson, Kamyar Kalantar-Zadeh, Kelly Helm, Dale Robinson, Bonnie Schneider, Philip Smith, Kjell Tullus, and Ali Poyan-Mehr received consultancy fees from Travere Therapeutics, Inc. for this work. Bridget L Balkaran and Adam K Jauregui are employees of Oracle Life Sciences, which received consultancy fees from Travere Therapeutics, Inc. for this work. Zheng-Yi Zhou, Nisha C. Hazra, Aolin Wang, Ian Nason, Chunyi Xu, Jingyi Liu are employees of Analysis Group, which received consultancy fees from Travere Therapeutics, Inc. for this work.
